Phase III
Jakafi hit the mark, meeting the trial’s primary endpoint of superior overall response rate (ORR) at Week 24 compared to best available therapy (BAT).
An antiviral drug, favipiravir, developed by Glenmark Pharmaceuticals, boosted the time it takes COVID-19 patients with mild to moderate symptoms to improve their health in a Phase III study.
Please check out the biopharma industry coronavirus (COVID-19) stories that are trending for July 24, 2020.
Francis Collins, the director of the NIH, told STAT they were “really well-powered, rigorously designed clinical trials.”
France’s GENFIT will discontinue the Phase III RESOLVE-IT study of elafibranor in this indication. Why they are shutting it down? Know all about it here.
AbbVie announced that its Rinvoq (upadacitinib) as a monotherapy hit both primary and all secondary endpoints in the second Phase III trial, Measure Up 2, in patients with moderate to severe atopic dermatitis.
Please check out the biopharma industry coronavirus (COVID-19) stories that are trending for July 22, 2020.
ACADIA Pharmaceuticals reported topline data from its Phase III CLARITY study of Nuplazid (pimavanserin) as an adjunctive treatment for major depressive disorder (MDD).
Please check out the biopharma industry coronavirus (COVID-19) stories that are trending for July 20, 2020.
It was a surprisingly big week for clinical trial updates related to COVID-19, although there was plenty of non-COVID-19 news as well. Here’s a look.
PRESS RELEASES